Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ADEPT: Phase II neo-adjuvant study of Androgen Deprivation Therapy (Degarelix) and Erdafitinib in high-risk localized prostate cancer.

Trial Profile

ADEPT: Phase II neo-adjuvant study of Androgen Deprivation Therapy (Degarelix) and Erdafitinib in high-risk localized prostate cancer.

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 12 Feb 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Degarelix (Primary) ; Erdafitinib (Primary)
  • Indications Prostate cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms ADEPT

Most Recent Events

  • 11 Feb 2021 Planned End Date changed from 30 Sep 2019 to 12 Mar 2021.
  • 11 Feb 2021 Status changed from recruiting to discontinued.Reason: The first phase of recruitment is complete. The end points from phase one were not met in order to continue to the second phase of recruitment.
  • 19 Jul 2019 Planned End Date changed from 1 Jan 2020 to 30 Sep 2019.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top